IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$4.19
-0.11 (-2.45%)
âŧ
5d:
-4.01%
30d:
+12.8%
90d:
+6.76%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IRWD is fairly priced but lacks strong directional signals. At -8.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IRWD is fairly priced but lacks strong directional signals. At -8.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.19
Based on 12.9% avg growth
INTRINSIC VALUE TODAY
$6.33
33.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $4.18, which is considered slightly high relative to its 30-day fair value range of $3.84 to $4.32. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.9) compared to its historical average (3.8). Remarkably, the market is currently pricing in an annual earnings decline of 8.4% over the next few years. This pessimistic expectation contrasts with the company's recent 125.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $3.96, while resistance sits at $4.50.
Market Sentiment: IRWD scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.10 (+42.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $3.96, while resistance sits at $4.50.
Market Sentiment: IRWD scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.10 (+42.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.84 -
$4.32
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
All Signals
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.2% below Wall St target ($6.10)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.84 -
$4.32
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.96
Resistance Level
$4.51
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.91
Wall Street Target
$6.10
(+42.2%)
Revenue Growth (YoY)
32.6%
Earnings Growth (YoY)
125.7%
Profit Margin
33.4%
Valuation Discount vs History
-8.4% cheaper
PE vs Historical
2.9 vs 3.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.4%
(market-implied from PE analysis)
1-Year Target
$3.93
(-8%)
2-Year Target
$3.60
(-16%)
3-Year Target
$3.30
(-23%)
3-Yr Target (if PE normalizes)
(PE: 3â4)
$4.30
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 21.8%)
$53.38
(+1144%)
Base:
(SPY PE: 2.9, Growth: 21.8%)
$7.74
(+81%)
Bear:
(PE: 2.5, Growth: 21.8%)
$6.58
(+53%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (6x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 5.52 | Current EPS (TTM): $0.75
Bull Case
$8.95
(+109%)
Analyst growth 96.4%, PE expands to 6.1
Base Case
$8.13
(+90%)
Market implied 96.4%, PE stable at 5.5
Bear Case
$2.82
(-34%)
Severe decline -20.0%, PE contracts to 4.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.9 to 3.8
Stabilization Target:
$5.60
(+30.5%)
PE Expansion Potential:
+30.5%
Share & Embed Analysis
Last updated: August 24, 2026 3:01 PM ET
Data refreshes hourly during market hours. Next update: 4:01 PM
Data refreshes hourly during market hours. Next update: 4:01 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander J Denner
SELL
6730800 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
